Difference between revisions of "Team:BostonU"
| Line 223: | Line 223: | ||
</div> | </div> | ||
<div class="slide-up-div"> | <div class="slide-up-div"> | ||
| − | <a class="wordmark" | + | <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/4/41/T--BostonU--LandingPageLogoRed.svg"></img></a> |
<div id="slide-up-wrapper"> | <div id="slide-up-wrapper"> | ||
<p>We explore the use of de novo designed riboriboregulators known as toehold switches to drive recombinase-based logic in cell-free TX-TL systems. We anticipate applications in point-of-care diagnostic technologies such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p> | <p>We explore the use of de novo designed riboriboregulators known as toehold switches to drive recombinase-based logic in cell-free TX-TL systems. We anticipate applications in point-of-care diagnostic technologies such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p> | ||
Revision as of 14:31, 7 August 2017
We explore the use of de novo designed riboriboregulators known as toehold switches to drive recombinase-based logic in cell-free TX-TL systems. We anticipate applications in point-of-care diagnostic technologies such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.
